Interferon-beta Modifies The Peripheral Blood Cell Cytokine Secretion In Patients With Multiple Sclerosis.

dc.creatorMirandola, Sandra R
dc.creatorHallal, Dannie E M
dc.creatorFarias, Alessandro S
dc.creatorOliveira, Elaine C
dc.creatorBrandão, Carlos O
dc.creatorRuocco, Heloisa H
dc.creatorDamasceno, Benito P
dc.creatorSantos, Leonilda M B
dc.date2009-Jul
dc.date2015-11-27T13:15:00Z
dc.date2015-11-27T13:15:00Z
dc.date.accessioned2018-03-29T01:08:29Z
dc.date.available2018-03-29T01:08:29Z
dc.identifierInternational Immunopharmacology. v. 9, n. 7-8, p. 824-30, 2009-Jul.
dc.identifier1878-1705
dc.identifier10.1016/j.intimp.2009.03.004
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/19289181
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/198227
dc.identifier19289181
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1298460
dc.descriptionImmunotherapy with Interferon-beta (IFNbeta) results in remarkably beneficial effects in patients with relapsing-remitting multiple sclerosis (MS), although the mechanisms by which it exerts these beneficial effects remain poorly understood. An investigation was made of the effects of IFNbeta on pro-inflammatory and anti-inflammatory cytokine production in peripheral blood cells in MS patients, both untreated and those undergoing immunotherapy, as well as in healthy controls. Results show a significant increase in the production of pro-inflammatory cytokines such as TNFalpha, IFNgamma and IL-12 in the plasma and in the supernatant of leukocyte cultures from MS patients with the untreated disease; IFNbeta administration significantly reduced the levels of TNFalpha and IFNgamma, with no changes in the level of IL-12. The Interferon-beta therapy also led to a significant increase in the production of IL-10, as well as a slight increase in that of TGFbeta. The reduction in pro-inflammatory cytokine production in the treated MS patient group, accompanied by a simultaneous increase in the production of anti-inflammatory cytokines and the reduction of relapse rates suggests that the beneficial effects of IFNbeta immunotherapy result, at least in part, from the modulation of cytokine patterns.
dc.description9
dc.description824-30
dc.languageeng
dc.relationInternational Immunopharmacology
dc.relationInt. Immunopharmacol.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdolescent
dc.subjectAdult
dc.subjectBrazil
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunotherapy
dc.subjectInterferon-beta
dc.subjectInterferon-gamma
dc.subjectInterleukin-10
dc.subjectInterleukin-12
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMultiple Sclerosis
dc.subjectNeutrophils
dc.subjectTumor Necrosis Factor-alpha
dc.titleInterferon-beta Modifies The Peripheral Blood Cell Cytokine Secretion In Patients With Multiple Sclerosis.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución